{"text": ["Analyst", "Report:", "Novartis", "AG"], "created_at": "2020-09-11 22:42:52"}
{"text": ["Where", "COVID-19", "vaccines", "stand", "following", "AstraZeneca", "setback"], "created_at": "2020-09-11 15:51:33"}
{"text": ["Novartis", "Stock", "Should", "Rise", "20%,", "Analyst", "Says"], "created_at": "2020-09-11 15:12:00"}
{"text": ["Novartis", "data", "show", "early", "treatment", "with", "Mayzent\u00ae", "(siponimod)", "delays", "disability", "progression", "and", "show", "benefits", "in", "cognitive", "performance", "in", "patients", "with", "secondary", "progressive", "multiple", "sclerosis", "(SPMS)"], "created_at": "2020-09-11 15:05:00"}
{"text": ["Novartis", "presents", "data", "at", "ACTRIMS-ECTRIMS", "for", "Kesimpta\u00ae", "(ofatumumab)", "in", "newly", "diagnosed", "treatment-na\u00efve", "adults", "with", "relapsing", "multiple", "sclerosis"], "created_at": "2020-09-11 15:00:00"}
